SynthesisInflammopharmacology2025
The therapeutic potential of terpenes in periodontal disease: a systematic review of pre-clinical animal studies.
Synthesis in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Periodontal disease is a chronic inflammatory condition affecting the supporting structures of the teeth, and has two main stages: gingivitis and periodontitis. Effective treatment for periodontal disease hinges on resolving inflammation, which can be challenging, patient-dependent. Recently, terpenes and their derivatives have emerged as promising alternatives for managing periodontal disease and its associated tissue complications. This review aims to collect preclinical studies and their recent advances in the biological effects and molecular mechanisms of terpenes in the context of periodontal disease. We performed a systematic and comprehensive search in PubMed, Scopus, Embase. A total of 13 non-clinical studies were included in this review. Information on the types of terpenes, the animals used, the dose and route of administration, the periodontal disease induction model, the samples collected and the observed outcomes. The prevalence of this compound was primarily observed in the regulation of inflammation, achieved through the attenuation of NF-κB, MAPK, and COX-related pathways. Additionally, its role in oxidative control was evidenced by the presence of the hydroxyl (-OH) group in the aromatic ring. Furthermore, the RANKL/RANK/OPG system was modulated by terpenes, which also induced sublethal damage to the cells of periodontopathogenic bacteria. Given their potential, terpenes are emerging as valuable compounds for treating periodontal disease and developing natural product-based medications. Nonetheless, improving the methodological quality of preclinical studies, especially in areas such as blinding and sample size determination, is essential to consolidate new findings.
Indexed as
Identifiers
41219631What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.